SPONSOR-REPORTED · JULY 23, 2026
Additional Phase 3 results announced
Lilly announced topline results from TRIUMPH-2 and TRIUMPH-3. A sponsor announcement is not FDA approval. S03: Retatrutide successful in two additional Phase 3 obesity trials
THE RETATRUTIDE WATCH · U.S. FOCUS
Follow the evidence.
Know what comes next.
A clear record of retatrutide research, regulatory milestones and what is—and is not—known. Original sources first. Forecasts labeled.
Looking for care now? Explore the separate current-care section.
Evidence, with provenance.FDA & federal recordsNIH / NLM resourcesLabeled sponsor announcementsHow we use sources →
01 / REGULATORY MILESTONES
A roadmap, not a countdown.
Submission, filing acceptance, FDA action and commercial availability are different events. None should be substituted for another.
PLANNED · JANUARY–MARCH 2027
U.S. application submission
Lilly’s August 5 update describes a planned Biologics License Application in Q1 2027. Plans can change. S02: Second-quarter 2026 results, Exhibit 99.1
NOT PUBLICLY CONFIRMED IN THIS REVIEW
FDA filing acceptance & review designation
No accepted application or retatrutide-specific target action date was identified in the sources reviewed for this snapshot.
FUTURE EVENT · OUTCOME UNKNOWN
FDA action
A review target is not a promise of approval. Additional information, delays, or a non-approval action remain possible. S04: PDUFA VII performance goals, section I.A.1, printed page 4
SEPARATE COMMERCIAL MILESTONE
Availability, labeling & access
Only report approved indications, launch, supply and access details after they are specifically confirmed. No retail launch date is asserted here.
02 / RETA SEARCH PULSE
Interest is measurable.
Approval is not a popularity contest.
A separate reading of relative Google search interest in “retatrutide”—not the number of prospective patients, drug buyers or visitors to RetaFinder.
Proposed method: United States · Web Search · All categories · rolling 52 complete weeks · weekly refresh.
How the pulse will work
Use a reviewed Google Trends website CSV export. Its 0–100 scale is relative to that export’s selected period and geography. A score of 100 is that window’s peak relative interest, not 100 searches or a 100% chance of approval. Keep whole-window snapshots; never append differently normalized exports. Google methodology: FAQ about Google Trends data Export guide: Export, embed, and cite Trends data
The four-week change compares two adjacent four-week means in the same export. Low-volume or incomplete data produce “insufficient data,” not invented numbers. Search interest is never fed into the FDA timing model.
03 / FROM THE RESEARCH DESK
The useful distinction.
REGULATORY EXPLAINER
A filing plan is not an approval date.
What Q1 2027 does—and does not—tell us about retatrutide’s potential review calendar.
FDA framework + Lilly statement · 3-minute readACCESS EXPLAINER
Research access and current care are different paths.
Find official trial and expanded-access information without confusing either with ordinary commercial supply.
FDA + NIH + official Lilly resources · 3-minute readSOURCE LITERACY
An official link is a source—not a seal of approval.
How to distinguish a regulator’s finding, a sponsor’s announcement and a paper indexed in PubMed.
NIH / NLM + editorial method · 3-minute readREGULATORY EXPLAINER
An FDA review framework glossary.
What the acronyms in retatrutide coverage actually mean—BLA, NDA, PDUFA, priority review, breakthrough, accelerated approval, REMS, advisory committee.
FDA framework + linked primary sources · 4-minute readRESEARCH ARCHIVE
Retatrutide milestones archive.
A dated, source-linked record of retatrutide research and sponsor announcements—each entry with publication and retrieval dates.
ClinicalTrials.gov + sponsor releases + FDA framework · 3-minute readCONVERSATION GUIDE
What to ask your clinician before any weight-loss intervention.
A pre-appointment question checklist—not medical advice. Use it to have a fuller conversation with the licensed clinician you have chosen.
NIH + clinician practice standards · 4-minute read04 / YOUR INBOX, YOUR CHOICE
RetaRegister
The evidence. The milestones. What remains unknown.
Follow the retatrutide story without joining a drug-access list. Or choose a separate current-care edition with clearly labeled directory promotions. Choose either, both, or neither.
Proposed cadence: one monthly edition, plus an extra notice for a material regulatory development. Articles remain readable without subscribing.
A newsletter concept—not a clinical registry, reservation, priority-access program or promise of treatment. No medical history is requested.
Choose your edition
By subscribing you confirm you have read the privacy notice and My Health My Data rights. Your email address combined with your edition choice may constitute consumer health data under Washington's My Health My Data Act. We use it only to send the edition(s) you selected. We do not sell or share it. Unsubscribe any time via the link in every email.
Privacy and consumer-health-data rights05 / OFFICIAL RESEARCH RESOURCES
Follow the official access information.
These links are educational, not paid trial placement or eligibility screening. A directory listing cannot establish access.
ClinicalTrials.gov
Read the original study record and contact details. Listing a study is not federal endorsement or a guarantee that a site is enrolling. S06: Finding a Clinical Trial
Search official trial records ↗Expanded access
Expanded access is distinct from routine prescribing and commercial approval. Read FDA’s explanation and Lilly’s current information; eligibility and availability require confirmation. S09: Expanded Access
FDA explanation ↗Lilly’s current access information ↗
ADVERTISEMENT · DIRECTORY-NETWORK PROMOTION
Explore care available today.
Follow tomorrow’s research. Discuss today’s options with a qualified clinician.
This is a commercial section, separate from the research desk. The publisher has business interests in the promoted directory network. These are not independent rankings or medical recommendations.
These categories are not substitutes for retatrutide or a determination that any treatment is appropriate for you. Services, licensure, prescribing and availability must be confirmed with the clinician. Most commercial exits remain held for destination review in this prototype; TRT-Finder has been activated after a destination review on 2026-09-16 (see Sources S23).
Advertising relationship. GLP-1Finder, HRT-Finder, TRT-Finder and Peptides-Finder are owned and operated by HormoneVentures, LLC. RetaFinder and those directories share common ownership; this is a separate editorial and product relationship, not an independent endorsement. Advertising standards
GLP-1Finder
Explore clinician and service information for weight-management care. No medication or prescription is guaranteed.
AD · glp-1finder.com · Review pendingHRT-Finder
Explore provider information for a conversation about menopause and hormone-related concerns. Not a treatment recommendation.
AD · HRT-Finder.com · Review pendingTRT-Finder
Explore provider information for evaluation of testosterone-related concerns. A directory cannot diagnose low testosterone.
Explore TRT-Finder ↗AD · trt-finder.com · Sponsored — HormoneVentures, LLC (common ownership)Peptides-Finder
Proposed route: a reviewed education page distinguishing approved products, investigational research and unapproved products—not a retatrutide seller list.
AD · peptides-finder.com · Held pending correctionProduction disclosure must identify the actual publisher and each ownership, referral or compensation relationship. Plain outbound links must not carry email addresses, subscriber IDs, health-topic tags or cross-site identifiers.
OUR PUBLISHING STANDARD
Facts get sources.
Unknowns stay unknown.
No unsupported approval countdown. No invented search volume. No drug sales. No automatic cross-enrollment. Corrections, source dates and commercial relationships belong in view—not in fine print.
Read the publishing and launch rules ↗